Physician profile
S Robert Bakall
NPI 1699814491
$7,998.80
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $670 · 2021: $1,344 · 2022: $1,891 · 2023: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,321.23 | 2019-2023 | Austedo, Austedo Xr |
| Alkermes, INC. | $1,254.26 | 2019-2023 | Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $874.38 | 2019-2023 | Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $799.76 | 2021-2023 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $771.19 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $725.14 | 2019 | |
| Allergan, INC. | $718.83 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $587.73 | 2019-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $234.96 | 2023 | Auvelity |
| Gilead Sciences, INC. | $225.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $162.70 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $100.00 | 2022 | |
| Eisai INC. | $98.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw S Bakall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.